�As children head back to the classroom, Health Canada is reminding parents of the importance of allergy awareness when wadding lunches for their children. Severe hypersensitive reactions can occur quickly and without warning, and some foods can be life-threatening to allergic children.
As many as 1.2 1000000 Canadians english hawthorn be unnatural by grievous allergies and these numbers racket are increasing, especially among children. Foods account for most children's allergies, with peanuts, tree nuts, sesamum indicum, soy, fish and seafood, wheat, egg and milk River being the most common food allergens.
When mortal ingests even a petite amount of an allergen, the symptoms of a reaction crataegus oxycantha develop quickly and can become very serious. The most grave symptoms include breathing difficulties, a drop in blood pressure, or shock, which may issue in loss of cognisance and fifty-fifty death.
Because of this, many elementary schools ar now restricting certain foods from students' lunches. Parents are encouraged to follow school policies, even if their baby is non allergic. To find kayoed which foods, if whatsoever, are restricted in their children's schools, parents should contact the school directly.
There is no cure for nutrient allergies. The only option is complete avoidance of the particular allergen. This is wherefore it is important that allergic children not be exposed to allergens that regularly effort extreme and sometimes fatal reactions.
Health Canada has a number of nutrient allergy factsheets which provide information on the priority food allergens. An It's Your Health article is also useable that provides additional information on severe allergic reactions.
Some of these hyperlinks provide approach to Web sites of organizations non subject to the Official Languages Act. The information found there is thence in the language of the website.
National allergic reaction associations, such as Anaphylaxis Canada, the Allergy Asthma Information Association or the Association Quebecoise des Allergies Alimentaires(French Only), also provide further information, including tips and strategies for educators, schools and other organizations for creating allergy safe communities.
Health Canada
More information
Tuesday 2 September 2008
Saturday 23 August 2008
MethylGene Provides Update On Suspension Of New Enrollment In MGCD0103 Clinical Trials
� MethylGene Inc. (TSX:MYG) announced that as a result of the home voluntary suspension of enrolment of modern patients into clinical trials evaluating MGCD0103, MethylGene and its development partner, Celgene Corporation, have been informed by the U.S. Food and Drug Administration (FDA) that the agency concurs with the action and is concomitantly placing a partial clinical hold on new patient enrollment for MGCD0103 clinical trials as it awaits the companies' submission of data and action plan to mitigate risk for patients.
A partial clinical hold is a check or hanging of only part of the clinical work requested under the investigational modern drug (IND) application (e.g., a specific protocol or region of a protocol is not allowed to continue; however, other protocols or parts of the protocol are allowed to go under the IND). Under the partial clinical contain, patients currently enrolled in MGCD0103 clinical trials wHO are confirmed to hold no signs or symptoms of pericarditis or pericardial effusion may continue in their several studies.
The companies had already begun to establish an action plan and data analysis package to submit to the FDA. The action plan with risk extenuation steps volition be communicated to regulative agencies and clinical investigators. Some of the stairs are expected to include specific steering for identifying patients at potential danger as good as management of patients who may develop pericarditis / pericardial effusion patch undergoing treatment with MGCD0103. MethylGene and Celgene ar working closely together with the FDA to complete this bundle and communicate it with the FDA to hold approval to commence registration of new patients as soon as possible.
About MGCD0103
MGCD0103 is an orally-administered, isoform-selective HDAC inhibitor. The compound is currently in multiple clinical trials: a Phase I trial in combination with Taxotere� for solid tumors; two Phase I/II trials, the first in combination with Vidaza� for hematological malignances and the moment with Gemzar� for pancreatic cancer; several Phase II monotherapy trials in haematological malignancies and, more lately, a Phase II, three-arm combination test with Vidaza in hematological malignancies. MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and has been designated an orphan medicinal product by the European Medicines Agency (EMEA) for the handling of Hodgkin lymphoma and AML.
About MethylGene
MethylGene Inc. (TSX: MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral, isoform-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I, Phase I/II and Phase II combination trials with Vidaza�, Gemzar� and Taxotere�. MGCD265 is an unwritten, multi-targeted kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases and is in Phase I clinical trials for firm tumor cancers. In add-on, MethylGene's preclinical programs let in: MGCD290, an HDAC inhibitor used in combination with azoles for fungal infections, a kinase inhibitor program for optic diseases, and a sirtuin inhibitor plan for malignant neoplastic disease. MethylGene's development and commercialization partners include Celgene Corporation, Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd. and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.
About Celgene
Celgene Corporation, based in Summit, New Jersey, is an integrated globose biopharmaceutical company engaged chiefly in the discovery, developing and commercialization of novel therapies for the discourse of cancer and rabble-rousing diseases through gene and protein rule. For more information, please visit the Company's web site at http://www.celgene.com.
Certain statements contained in this news waiver, other than statements of fact that are severally verifiable at the date hereof, may constitute innovative statements. Such statements, based as they are on the stream expectations of management of MethylGene, inherently involve legion risks and uncertainties, known and nameless, many of which ar beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but ar not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the winner, efficacy or safety of MGCD0103, MGCD265 or MGCD290; the ability to scale up, word and manufacture sufficient GMP, clinical or commercialization quantities of MGCD0103, MGCD265 or MGCD290, and the congener success or the lack of success in developing and gaining regulatory blessing and/or market place acceptance for any combine or new product including MGCD0103, MGCD265 or MGCD290. Such risks include, merely are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulative environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our
A partial clinical hold is a check or hanging of only part of the clinical work requested under the investigational modern drug (IND) application (e.g., a specific protocol or region of a protocol is not allowed to continue; however, other protocols or parts of the protocol are allowed to go under the IND). Under the partial clinical contain, patients currently enrolled in MGCD0103 clinical trials wHO are confirmed to hold no signs or symptoms of pericarditis or pericardial effusion may continue in their several studies.
The companies had already begun to establish an action plan and data analysis package to submit to the FDA. The action plan with risk extenuation steps volition be communicated to regulative agencies and clinical investigators. Some of the stairs are expected to include specific steering for identifying patients at potential danger as good as management of patients who may develop pericarditis / pericardial effusion patch undergoing treatment with MGCD0103. MethylGene and Celgene ar working closely together with the FDA to complete this bundle and communicate it with the FDA to hold approval to commence registration of new patients as soon as possible.
About MGCD0103
MGCD0103 is an orally-administered, isoform-selective HDAC inhibitor. The compound is currently in multiple clinical trials: a Phase I trial in combination with Taxotere� for solid tumors; two Phase I/II trials, the first in combination with Vidaza� for hematological malignances and the moment with Gemzar� for pancreatic cancer; several Phase II monotherapy trials in haematological malignancies and, more lately, a Phase II, three-arm combination test with Vidaza in hematological malignancies. MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and has been designated an orphan medicinal product by the European Medicines Agency (EMEA) for the handling of Hodgkin lymphoma and AML.
About MethylGene
MethylGene Inc. (TSX: MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral, isoform-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I, Phase I/II and Phase II combination trials with Vidaza�, Gemzar� and Taxotere�. MGCD265 is an unwritten, multi-targeted kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases and is in Phase I clinical trials for firm tumor cancers. In add-on, MethylGene's preclinical programs let in: MGCD290, an HDAC inhibitor used in combination with azoles for fungal infections, a kinase inhibitor program for optic diseases, and a sirtuin inhibitor plan for malignant neoplastic disease. MethylGene's development and commercialization partners include Celgene Corporation, Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd. and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.
About Celgene
Celgene Corporation, based in Summit, New Jersey, is an integrated globose biopharmaceutical company engaged chiefly in the discovery, developing and commercialization of novel therapies for the discourse of cancer and rabble-rousing diseases through gene and protein rule. For more information, please visit the Company's web site at http://www.celgene.com.
Certain statements contained in this news waiver, other than statements of fact that are severally verifiable at the date hereof, may constitute innovative statements. Such statements, based as they are on the stream expectations of management of MethylGene, inherently involve legion risks and uncertainties, known and nameless, many of which ar beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but ar not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the winner, efficacy or safety of MGCD0103, MGCD265 or MGCD290; the ability to scale up, word and manufacture sufficient GMP, clinical or commercialization quantities of MGCD0103, MGCD265 or MGCD290, and the congener success or the lack of success in developing and gaining regulatory blessing and/or market place acceptance for any combine or new product including MGCD0103, MGCD265 or MGCD290. Such risks include, merely are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulative environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our
Wednesday 13 August 2008
Download Jesse Dayton
 Artist: Jesse Dayton: mp3 download Genre(s): Rock Country Discography:  Country Soul Brother Year: 2004 Tracks: 12  Tall Texas Tales Year: 2000 Tracks: 15 Raised in Beaumont, TX, nigh the childhood home of George Jones, Jesse Dayton grew up on the hard-core honkey tonk of Jones, Hank Williams, Sr., and Lefty Frizzell, but too blues artists such as Lightnin' Hopkins and Mance Lipscomb. During the tardy '80s and early '90s Dayton fronted two rockabilly bands, the Roadkings and the Alamo Jets, playing around the country in whitey tonks and dives. After commencement a solo life chronicle, he played support slots at shows by Willie Nelson, Merle Haggard, and Waylon Jennings, and fifty-fifty appeared as the bandleader in a Pam Tillis video. Signed to Justice Records in 1995, he released Raisin' Cain that same year and besides appeared on the Willie Nelson testimonial record, Twisted Willie. Dayton's songs as well appeared in the FOX-TV series Melrose Place and in the film Scourge of the Starving Class. In fall 2000, Dayton issued Grandiloquent Texas Tales. Hey Nashvegas followed in 2001, and Country Soul Brother in 2004. That same year Dayton received an interesting sound call darn en route to a gig. It was Rob Zombie life history, and he wanted to know if Jesse would spell some songs for a scene show he was on the line on. The result was Rob Zombie Presents…Banjo & Sullivan: The Ultimate Collection 1972-1978, released in June 2005 to coincide with Devil's Rejects, Zombie's subsequence to his 2003 cinematic debut Home of a chiliad Corpses. In the film's exposit, inventive backstory, Roy Sullivan and Adam "Fingers" Banjo were barrelhouse musicians wHO met their sanguineous end at the work force of the murderous ring known as the Devil's Rejects. Zombie commissioned Dayton to write and do a series of songs as Banjo & Sullivan, and the result were tongue-in-cheek, only well-done barrelhouse book of Numbers like "Dick Soup", "Noble Don't Let Me Die in a Cheap Motel," and "I'm at Home Getting Hammered [Spell She's Out Getting Nailed]." The album even included a cover of "Freebird". |
Kaiser Chiefs Star Ricky Wilson Slams 'Boring' Indie Bands
Wednesday 6 August 2008
Il Divo preps new album for Nov. 18
Songs volition be sung in Italian, Spanish and English
NEW YORK -- Superstar vocal radical Il Divo is eyeing a Nov. 18 release for its next Syco/Columbia studio album.
The as-yet-untitled set was produced by Steve Mac, world Health Organization has worked with Il Divo on several prior projects. Among the tracks expected to appear are "Bridge Over Troubled Water," "Amazing Grace" and "Hallelujah." Also making an appearing is Frankie Goes to Hollywood's "The Power of Love," which songwriters Holly Johnson and Trevor Horn have never previously approved for a cover.
According to a interpreter, the record album will feature material principally sung in Spanish, English and Italian, and a superstar-level duet is too in the cards.
Il Divo's most recent album, 2006's "Siempre," has sold more than 1 million copies in the U.S., according to Nielsen SoundScan.
NEW YORK -- Superstar vocal radical Il Divo is eyeing a Nov. 18 release for its next Syco/Columbia studio album.
The as-yet-untitled set was produced by Steve Mac, world Health Organization has worked with Il Divo on several prior projects. Among the tracks expected to appear are "Bridge Over Troubled Water," "Amazing Grace" and "Hallelujah." Also making an appearing is Frankie Goes to Hollywood's "The Power of Love," which songwriters Holly Johnson and Trevor Horn have never previously approved for a cover.
According to a interpreter, the record album will feature material principally sung in Spanish, English and Italian, and a superstar-level duet is too in the cards.
Il Divo's most recent album, 2006's "Siempre," has sold more than 1 million copies in the U.S., according to Nielsen SoundScan.
Monday 23 June 2008
The Drill
Artist: The Drill
Genre(s):
House
Discography:
Queen Bee (DEST20DJX01)
Year: 2007
Tracks: 2
One More Night (CDS)
Year: 2006
Tracks: 3
The Drill _Incl Tom Novy Remixes CDM
Year: 2005
Tracks: 5
Monday 16 June 2008
Will Glastonbury Give Amy Winehouse Gangrene?
If you thought Amy Winehouse’s face couldn’t possibly get any worse, you’d be wrong. Experts are warning her to be careful at the Glastonbury festival for fear her mug could be gangrenous.
The scabby singer is due to play a set at the notoriously muddy music event, although the brown sludge could prevent her from enjoying it if the cuts on her arms and face become infected.
An insider told the Daily Star that medics are worried because infected cuts can lead to gangrene, an appalling condition which, if untreated, can lead to amputation of limbs.
Amy has been advised to take a nurse with her to the remote site to mummify her in bandages should her condition worsen.
Do you think Amy should take better care of herself? Be sure to leave your comments below.
The scabby singer is due to play a set at the notoriously muddy music event, although the brown sludge could prevent her from enjoying it if the cuts on her arms and face become infected.
An insider told the Daily Star that medics are worried because infected cuts can lead to gangrene, an appalling condition which, if untreated, can lead to amputation of limbs.
Amy has been advised to take a nurse with her to the remote site to mummify her in bandages should her condition worsen.
Do you think Amy should take better care of herself? Be sure to leave your comments below.
Friday 6 June 2008
Passion drives music
Tackling important social issues is an important part of the songwriting process for Crash Parallel
Singer/songwriter Tim Edward says one the goals band members had when they entered the studio to record debut album World We Know � which was released by Sony BMG last month � was to discuss topics that they each felt passionate about.
�Most of it is real personal stuff, some stories are sort of an extension of something that�s real, but most of the stories are very real in my life,� Edwards tells Metro.
�A lot of them have to do with things I�ve gone through, things I�ve experienced or observed, and some things are inspired by stories that other people have told me.�
The Toronto-based alternative rock act, which also includes songwriter/guitarist Dan Saitua, bassist Gary Rugula and drummer John Vitellaro, are currently touring Canada, but return to town for a gig at The Kool Haus on June 8.
Edwards says the debut incorporates strong melodies and intimate lyrics by drawing inspiration from influences such as Coldplay, David Gray and Pearl Jam. The diverse range of songs on the album at times highlight opinions on social and political issues, but are also inspired by matters of the heart and the challenge of dealing with complicated and difficult relationships, people and situations
�Part of the fun is writing stories that people can relate to or (have) gone through so that at the end of the day people are getting something out of your music,� Edwards says.
The band�s first single World We Know, jumped from No. 3 spot to No. 1 The Billboard Emerging Canadian Artist Chart days before the album�s release.
See Also
Subscribe to:
Posts (Atom)